CXCR4 inhibitor attenuates allergen-induced lung inflammation by down-regulating MMP-9 and ERK1/2

Huilong Chen1, Xiangqin Xu1, Jieming Teng1

  • 1Department of Respiratory and Critical Care Medicine, Tongji Hospital, Key Laboratory of Pulmonary Diseases of Health Ministry, Tongji Medical College, Huazhong University of Science and Technology Wuhan, China.

Insights

Chemokine CXCL12/CXCR4 signaling drives allergic airway inflammation by increasing MMP-9. Blocking CXCR4 with AMD3100 reduced asthma symptoms and MMP-9 expression in a mouse model.

Area of Science:

  • Immunology
  • Respiratory Medicine
  • Molecular Biology

Background:

  • Chemokine (C-X-C motif) ligand 12 (CXCL12) and its receptor chemokine receptor 4 (CXCR4) are implicated in bronchial asthma pathogenesis.
  • The precise molecular mechanisms linking CXCL12/CXCR4 signaling to asthma remain incompletely understood.

Purpose of the Study:

  • To elucidate the role of CXCL12/CXCR4 signaling in mediating allergic airway inflammation.
  • To investigate the downstream molecular pathways involved in CXCL12/CXCR4-induced asthma responses.

Main Methods:

  • Utilized a murine model of ovalbumin (OVA)-induced asthma.
  • Administered AMD3100, a CXCR4 antagonist, to assess its therapeutic effect.
  • Examined matrix metalloproteinase 9 (MMP-9) expression in epithelial cells and lung tissue.
  • Investigated the synergistic effects of CXCL12/CXCR4 signaling and IL-13 in 16HBE cells.
  • Analyzed the involvement of ERK1/2 signaling pathways.

Main Results:

  • CXCL12/CXCR4 signaling was found to mediate allergic airway inflammation through the induction of MMP-9.
  • AMD3100 treatment significantly reduced OVA-induced asthmatic responses and epithelial MMP-9 expression.
  • CXCL12/CXCR4 signaling synergized with IL-13 to enhance MMP-9 expression in bronchial epithelial cells.
  • CXCL12/CXCR4 signaling promotes MMP-9 expression via ERK1/2 activation.

Conclusions:

  • CXCL12/CXCR4 signaling plays a significant role in the development of bronchial asthma.
  • Targeting the CXCL12/CXCR4 pathway, specifically with CXCR4 antagonists, may offer a therapeutic strategy for asthma.
  • Understanding the CXCL12/CXCR4-MMP-9-ERK1/2 axis provides novel insights into asthma pathogenesis.

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K